AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$DVA

Waters Kathleen Alyce sold $3.2M of DVA

Waters Kathleen Alyce (Chief Legal & Pub. Affairs Off) sold 15,405 shares of DAVITA INC. (DVA) at an average of $208.40 ($207.84–$209.17, $3.21M total) across 2 trades on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Waters Kathleen Alyce
Published Jun 17, 2026, 10:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 10:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$DVA
Neutral
high confidence
Mentioned
$DVA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DVANeutralLow
01

Why it matters

The disclosed open-market sale is primarily a transparency datapoint; without additional company news, it is unlikely to materially change valuation drivers.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone does not introduce a new fundamental catalyst.

03

What to watch

The article provides only the sale details; it does not include any offsetting insider buys, changes in guidance, or other fundamental updates that would contextualize the selling.

Relevance 5/10Novelty 5/10Timing: Filed 2026-06-17; sale executed 2026-06-15.

Background

The article is an SEC Form 4 insider transaction disclosure for DaVita, reported by an officer under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$DVANeutralHigh confidence
Context

DaVita insider (Chief Legal & Public Affairs Officer) sold 15,405 shares in open-market trades under a pre-arranged 10b5-1 plan for ~$3.21M.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a Form 4 detailing a planned 10b5-1 sale with no accompanying company-specific operational/regulatory catalyst in the text.

Market effects

Sector

Minimal—this is company-specific insider transaction disclosure with no sector-wide read-across provided.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even planned 10b5-1 sales can coincide with private information; traders may still treat the disclosure as a mild negative signal for positioning.

Key entities

  • company
    DAVITA INC.

    Issuer of the Form 4 insider transaction; officer sold 15,405 shares for ~$3.21M under a 10b5-1 plan.

  • insider
    Waters Kathleen Alyce

    Chief Legal & Public Affairs Officer who executed the open-market sale(s).

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

DVA insider trading history →

Related articles

$DVAMed

Washington state accuses largest dialysis providers DaVita, Fresenius of suppressing competition

Washington state sued DaVita and Fresenius Medical Care, alleging they suppress competition by requiring nephrologists to sign noncompete agreements, reducing patient treatment options. The state seeks to void these agreements and impose fines. DaVita denies wrongdoing; Fresenius did not comment. The FTC is also investigating. DaVita operates 51 centers in Washington, Fresenius 29, with some areas having only one provider.

finance.yahoo.com
$DVAMedAI 8/10

DaVita (DVA) Q3 2026 Earnings Call Transcript

DaVita (DVA) reported Q3 2026 adjusted operating income of $561M and EPS of $3.82. The company highlighted clinical advancements in fluid management and expanded HD dialyzers, expecting a national rollout by November. DaVita raised its Integrated Kidney Care (IKC) guidance to $65M for 2026, citing improved savings rates and partnerships. Full-year 2026 adjusted operating income is projected to be $2.175B-$2.25B, with EPS between $14.30-$15.20.

finance.yahoo.com
$DVAHighAI 9/10

What DaVita (DVA) Said on Its Q3 Earnings Call

DaVita (DVA) reported Q3 earnings, highlighting a 20% year-over-year increase in technology spending and a national rollout of expanded hemodialysis dialyzers. The company expects technology investment growth to decelerate but not decline in 2027. DaVita raised its outlook for Integrated Kidney Care, projecting at least $65 million in adjusted operating income for 2026.

finance.yahoo.com
$DVAHighAI 8/10

DaVita Inc (DVA) (Q3 2026) Earnings Call Highlights: IKC Guidance Raised, Expanded HD

DaVita Inc (DVA) narrowed its 2026 adjusted operating income and EPS guidance due to higher US dialysis costs. Revenue per treatment grew 1.1% YoY, while patient care costs rose 2.4%. The new ESRD rule's 3.5% rate increase is expected to have a net impact of 1.5% to 2% for 2027. CEO Javier Rodriguez highlighted growth plans for the IKC business and the company's stance on the HHS Kidney Care National Plan.

finance.yahoo.com
$DVAHighAI 9/10

DaVita’s (NYSE:DVA) Q3 2026: beats on revenue but stock drops

DaVita (DVA) reported Q3 2026 revenue of $3.58B, beating estimates by 1.7% YoY. Adjusted EPS of $3.82 exceeded expectations by 6.9%. Management raised full-year EPS guidance to $14.75. Operating margin remained steady at 14%, but free cash flow margin declined to 7.7% from 19.7% YoY. Sales volumes increased 1.2% YoY, reversing a prior decline.

finance.yahoo.com